Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity
dc.contributor.author | Peters, Barry S. | |
dc.contributor.author | Jaoko, Walter | |
dc.contributor.author | Vardas, Eftyhia | |
dc.contributor.author | Panayotakopoulos, George | |
dc.contributor.author | Fast, Patricia | |
dc.contributor.author | Schmidt, Claudia | |
dc.contributor.author | Gilmour, Jill | |
dc.contributor.author | Bogoshi, Mampedi | |
dc.contributor.author | Omosa-Manyonyi, Gloria | |
dc.contributor.author | Dally, Len | |
dc.contributor.author | Klavinskis, Linda | |
dc.contributor.author | Farah, Bashir | |
dc.contributor.author | Tarragona, Tony | |
dc.contributor.author | Bart, Pierre-Alexandre | |
dc.contributor.author | Robinson, Andrew | |
dc.contributor.author | Pieterse, Colleen | |
dc.contributor.author | Stevens, Wendy | |
dc.contributor.author | Thomas, Richard | |
dc.contributor.author | Barin, Burc | |
dc.contributor.author | McMichael, Andrew J. | |
dc.contributor.author | McIntyre, James A. | |
dc.contributor.author | Pantaleo, Giuseppe | |
dc.contributor.author | Hanke, Tom´aˇs | |
dc.contributor.author | Bwayo, JJ | |
dc.date.accessioned | 2013-02-14T09:58:04Z | |
dc.date.available | 2013-02-14T09:58:04Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | Elsevier | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/9864 | |
dc.description.abstract | Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of 25 overlapping CD8+ T cell epitopes (HIVA). Methods: These studies compared intramuscular, subcutaneous, and intradermal MVA at dosage levels ranging from 5×106–2.5×108 pfu. In Study IAVI-010, DNA vaccine was given as a prime at months 0 and 1, followed by MVA as a boost at months 5 and 8. In Study IAVI-011, MVA alone was given at months 0 and 2. Regular safety monitoring was performed. Immunogenicity was measured by the interferon (IFN)- ELISPOT assay on peripheral blood mononuclear cells (PBMC). Results: No serious adverse events were attributed to either vaccine; most adverse events were mild or moderate, although MVA resulted in some severe local reactions. Five vaccine recipients had at least one positive IFN- ELISPOT response, but none were sustained. Conclusion: This HIV-1 vaccine candidate was in general safe and well-tolerated. Local reactions were common, but tolerable. Detectable immune responses were infrequent | en |
dc.language.iso | en | en |
dc.subject | Prophylactic HIV-1 vaccine; | en |
dc.subject | safety; | en |
dc.subject | Immunogenicity; | en |
dc.subject | prime-boost; | en |
dc.subject | MVA (modified vaccinia virus Ankara); | en |
dc.subject | DNA vaccine | en |
dc.title | Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity | en |
dc.type | Article | en |
Files in this item
This item appears in the following Collection(s)
-
Faculty of Health Sciences (FHS) [10378]